An evaluation of voclosporin for the treatment of lupus nephritis

  title={An evaluation of voclosporin for the treatment of lupus nephritis},
  author={Fang En Sin and David Alan Isenberg},
  journal={Expert Opinion on Pharmacotherapy},
  pages={1613 - 1621}
  • F. Sin, D. Isenberg
  • Published 12 September 2018
  • Medicine
  • Expert Opinion on Pharmacotherapy
ABSTRACT Introduction: Lupus nephritis (LN) is associated with significant morbidity and mortality. Current treatment outcomes remain suboptimal. No disease modifying medications are licensed for the treatment of LN. Voclosporin, a novel calcineurin inhibitor, has been investigated as induction therapy in LN in combination with myocophenolate mofetil (MMF) and a glucocorticoid (GC). Two phase II trials of voclosporin were the first trials of a potential treatment of active LN that met their… 
Individualizing Therapy in Lupus Nephritis
Recent advances in immunotherapies for lupus nephritis
The data supporting regulatory approval for belimumab, a monoclonal antibody targeting the B cell survival cytokine BAFF (B cell activating factor), and voclosporin, a cyclosporin analog with improved pharmacokinetic characteristics are summarized.
Lupus nephritis: challenges and progress.
PURPOSE OF REVIEW The management of lupus nephritis remains unsatisfactory due to insufficiently effective treatment regimens and the dearth of reliable predictors of disease onset or progression to
A glimpse into the future of systemic lupus erythematosus
This viewpoint article on a forecast of clinically meaningful changes in the management of systemic lupus erythematosus (SLE) in the next 10 years is based on a review of the current state of the
Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy
Developments in the understanding of tubulointerstitial injury and repair are yielding new strategies for preserving renal function and preventing fibrosis, and improvements in risk assessment using genetic or transcriptomic biomarkers could enable the design of clinical trials to prevent LN onset and progression.
A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies
Recent advances in the understanding of disease pathogenesis in lupus nephritis are discussed in the context of potential emerging therapies.
Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies
  • J. Wenzel
  • Biology, Medicine
    Nature Reviews Rheumatology
  • 2019
Insights into the cellular and molecular pathogenesis of cutaneous lupus erythematosus have triggered the development of new therapeutic strategies, including targeted treatment strategies that mainly target type I interferon-producing cells and their pathways.
2021 FDA TIDES (Peptides and Oligonucleotides) Harvest
In this review, the approved TIDE-based drugs are analyzed on the basis of their chemical structure, medical target, mode of action, administration route, and adverse effects.


Immunosuppressive treatment for proliferative lupus nephritis.
The effects of all treatment strategies on death (all causes) and ESKD were uncertain and the benefits and harms of different immunosuppressive treatments in people with biopsy-proven lupus nephritis were evaluated.
A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years.
For patients with diffuse proliferative lupus nephritis, azathioprine or cyclosporine combined with corticosteroids demonstrated equal efficacy in the prevention of flares.
Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up
TAC is non-inferior to MMF, when combined with prednisolone, for induction therapy of active LN, and with azathioprine maintenance for 5 years, a non-significant trend of higher incidence of renal flares and renal function decline is observed with the TAC regimen.
Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.
  • R. PepperM. Griffith T. Cairns
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2009
This data demonstrates the efficacy of a rituximab and MMF based regime in the treatment of lupus nephritis, allowing a reduction or total withdrawal of corticosteroids.
Multitarget Therapy for Induction Treatment of Lupus Nephritis
The multitarget induction regimen demonstrated a higher incidence of complete remission and overall response in patients with concurrent class IV and V LN compared with intravenous cyclophosphamide (IVCY) and steroids, and the multitarget therapy group experienced fewer adverse events than the IVCY group.
Rituximab: the Lupus Journey
The road travelled by rituximab as a lupus treatment in the past 14 years is reviewed and where the journey is heading is considered.
The PROMISE Study: A Phase 2b Multicenter Study of Voclosporin (ISA247) Versus Tacrolimus in De Novo Kidney Transplantation
  • S. BusqueM. Cantarovich H. Meier‐Kriesche
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2011
This 6‐month study shows VCS to be as efficacious as TAC in preventing acute rejection with similar renal function in the low‐ and medium‐exposure groups, and potentially associated with a reduced incidence of NODAT.
The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE.
Ciclosporin was not a more effective corticosteroid-sparing agent than AZA in patients with SLE, but may be considered in patients who are unable to tolerate AZA.
Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
Data from the AIR registry show a satisfactory tolerance profile and clinical efficacy of RTX in patients with SLE, leaving open the question of the therapeutic use of RTX in SLE.
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
The data from the ELNT indicate that in European SLE patients with proliferative lupus nephritis, a remission-inducing regimen of low-dose IV CYC (cumulative dose 3 gm) followed by AZA achieves clinical results comparable to those obtained with a high-dose regimen.